Intravenous Immunoglobulin for Guillain-Barré Syndrome: How Effective?

Guillain-Barré syndrome is an acute inflammatory demyelinating neuropathy characterized by progressive symmetric polyradiculoneuritis, predominantly manifested by weakness and areflexia. In this article, we report our findings in 25 children treated with intravenous immunoglobulin and compare them with the remaining 30 children who received supportive care only. Only supportive care was given to 30 children who were not able to receive intravenous gammaglobulin because of shortcomings in intravenous gammaglobulin availability owing to a poor import during those years. Twenty-five patients were treated with intravenous gammaglobulin; they received intravenous gammaglobulin 0.4 g/kg/day for 5 consecutive days. Seventeen of the intravenous gammaglobulin group had received intravenous gammaglobulin within 10 days after the first symptoms, and eight of them had received intravenous gammaglobulin after the first 10 days. The average time elapsed for the symptoms to reach the maximum level was 6.9 (range 4—12) days in patients receiving intravenous gammaglobulin in the first 10 days, and it was significantly shorter than the time elapsed for the supportive care group (6.9 versus 8.8 days, respectively) (P < .05). Admission to the hospital after the first symptom, disability grade, time to improve in disability grade, the period of hospitalization, and mortality were not different in the intravenous gammaglobulin and supportive care groups (P > .05). Our suggestion for intravenous gammaglobulin treatment in Guillain-Barré syndrome is that if the patient has risk factors for respiratory insufficiency, then the treatment should be started. We more confidently carry out the follow-up of these patients after the results of this study. In conclusion, although it has been reported that intravenous gammaglobulin facilitates improvement in the disease and the decrease in mortality in children with Guillain-Barré syndrome, it has been mentioned in some studies that the intravenous gammaglobulin treatment was not better than supportive care, as in our study. However, further studies are essential to determine when intravenous gammaglobulin should be given to patients having which clinical and laboratory findings. (J Child Neurol 2006;21:972—974; DOI 10.2310/ 7010.2006.00214).

[1]  H. Jones.  Topical Review: Childhood Guillain-Barré Syndrome: Clinical Presentation, Diagnosis, and Therapy , 1996 .

[2]  A. Afifi,et al.  Childhood Guillain-Barré Syndrome: Clinical and Electrophysiologic Features Predictive of Outcome , 2001, Journal of child neurology.

[3]  J. Sladky,et al.  The role of plasmapheresis in childhood guillain‐barré syndrome , 1990, Annals of neurology.

[4]  Y. Sakakihara,et al.  AGE‐ASSOCIATED CHANGES IN THE SYMPTOMATOLOGY OF GUILLAIN‐BARRÉ SYNDROME IN CHILDREN , 1991, Developmental medicine and child neurology.

[5]  A. Ropper.  Severe acute Guillain‐Barré syndrome , 1986, Neurology.

[6]  E. Wijdicks,et al.  Fatal Guillain-Barré syndrome , 1999, Neurology.

[7]  R. Hughes,et al.  Plasma exchange versus intravenous immunoglobulin for Guillain-Barré syndrome. , 1997, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[8]  S. Azen,et al.  Early predictors of incomplete recovery in children with Guillain-Barr'e polyneuritis. , 1975, The Journal of pediatrics.

[9]  J. Pollard,et al.  Peripheral Neuropathy in Childhood , 1999 .

[10]  S. Ashwal,et al.  Guillain-Barré syndrome in childhood: natural course and efficacy of plasmapheresis. , 1993, Pediatric neurology.

[11]  D. Cornblath,et al.  Assessment of current diagnostic criteria for Guillain‐Barré syndrome , 1990, Annals of neurology.

[12]  H. Johnston,et al.  Plasmapheresis in children with Guillain‐Barré syndrome , 1991, Neurology.

[13]  G. Hankey,et al.  Guillain–Barré syndrome in Western Australia, 1980–1985 , 1987, The Medical journal of Australia.

[14]  A. Kalaycı,et al.  Intravenous immunoglobulin treatment in children with Guillain-Barre syndrome. , 1995, Scandinavian journal of infectious diseases.

[15]  H. Arroyo,et al.  Severe Guillain-Barré syndrome in childhood treated with human immune globulin. , 1996, Pediatric neurology.

[16]  Y. Sakakihara,et al.  High‐dose immunoglobulin therapy for Guillain−Barré syndrome in Japanese children , 2003, Pediatrics international : official journal of the Japan Pediatric Society.

[17]  J. Katz,et al.  Outcome in severe pediatric Guillain-Barré syndrome after immunotherapy or supportive care , 1999, Neurology.

[18]  D. Briscoe,et al.  Prognosis in Guillain-Barré syndrome. , 1987, Archives of disease in childhood.

[19]  J. de Jonge,et al.  The natural history of the Guillain-Barré syndrome in 18 children and 50 adults. , 1989, Journal of neurology, neurosurgery, and psychiatry.

[20]  G. Kanra,et al.  Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome. , 1997, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[21]  R. Korinthenberg,et al.  Natural history and treatment effects in Guillain-Barré syndrome: a multicentre study. , 1996, Archives of disease in childhood.

[22]  H. Jones,et al.  Guillain–Barré syndrome in children: Clinical course, electrodiagnosis, and prognosis , 1992, Muscle & nerve.

[23]  D. Matthew,et al.  Prognosis in severe Guillain-Barré syndrome. , 1987, Archives of disease in childhood.

[24]  J. Vajsar,et al.  Long-term outcome in children with Guillain-Barré syndrome. , 2003, The Journal of pediatrics.

[25]  D. Zafeiriou,et al.  Single dose immunoglobulin therapy for childhood Guillain-Barrésyndrome , 1997, Brain and Development.

[26]  E. Wood,et al.  Plasmapheresis vs intravenous immunoglobulin treatment in childhood Guillain-Barré syndrome. , 1994, Archives of pediatrics & adolescent medicine.